Caprion Biosciences and the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium have partnered to track early Alzheimer’s disease progression by measuring biomarkers in patients with mild cognitive impairment (MCI) and full-blown Alzheimer’s disease. The team will build on results from an earlier collaboration that used Caprion’s multiple reaction monitoring (MRM) mass spectrometry-based platform to quantify 142 candidate protein biomarkers in Alzheimer’s and MCI patients as well as in healthy controls. The two organizations have selected five high-performing biomarkers from this data set to focus on in the new study. Caprion will use its CNS ProteoCarta MRM biomarker panel to measure the concentration of these proteins in samples collected over a 3-year or greater period from more than 200 subjects from the Alzheimer’s Disease Neuroimaging Initiative. The collaboration will then correlate the biomarker changes over time with imaging and clinical data to assess the ability of the biomarkers to accurately track natural disease progression.